Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Roivant Sciences $150 million equity offering
We advised the company on its debut SEC-registered primary and secondary offering
Akoya Biosciences $50 million at-the-market program
The common stock is listed on the Nasdaq Global Select Market
Molded Devices acquisition of GlobalMed and Schauenburg-Truplast
We advised Molded Devices on the acquisition and the related financing arrangements
Elevance Health $1.8 billion senior notes offering
The investment-grade notes are due 2025, 2032 and 2052
Walgreens $2.25 billion Summit Health-CityMD acquisition financing
We are advising the lender in connection with the facilities
NextGen Healthcare $275 million convertible senior notes offering
The 3.75% convertible notes are due 2027
Johnson & Johnson $16.6 billion acquisition of Abiomed
We are advising J.P. Morgan Securities as financial adviser to Johnson & Johnson
Recursion Pharmaceuticals $150 million private placement
We advised the placement agents on the private placement of common stock
Prime Medicine $175 million IPO
The shares are listed on the Nasdaq Global Market
Denali Therapeutics $316 million follow-on offering
The shares are listed on the Nasdaq Global Select Market